Business Context and Reporting Period
This Form 8-K was filed by Novelos Therapeutics, Inc. (not Cellectar Biosciences, Inc., as noted in the metadata) on March 26, 2008. The report details the entry into a material definitive agreement for a private placement financing round.
Key Financial Metrics and Transaction Details
- Financing Amount: $5,000,000 aggregate purchase price.
- Securities Issued: 100 shares of Series D Convertible Preferred Stock and warrants to purchase 3,846,151 shares of common stock.
- Conversion/Exercise Price: $0.65 per share for both Series D Preferred Stock and warrants.
- Dividend Rate: 9% annual dividend on Series D Preferred Stock, payable semi-annually (cash or stock at company option).
- Placement Fee: 2% of gross proceeds paid to Rodman & Renshaw LLC.
- Debt Covenants: Company prohibited from incurring new debt exceeding $500,000 while Series D Preferred Stock is outstanding.
Material Changes and Corporate Actions
- Board Composition: Xmark Opportunity Fund entities gain the right to designate one Board member; Lead Investors gain the right to designate one Board observer.
- Stock Exchange: Existing Series B Preferred Stock holders will exchange their shares for Series D Preferred Stock.
- Waiver of Damages: Series B holders waived accrued liquidated damages regarding the failure to register shares for resale from September 7, 2007, through the closing date.
- Restrictions: The company is restricted from paying common stock dividends, issuing equity below $0.65, or selling substantially all assets without maintaining Series D rights.
Guidance, Risks, and Contingencies
- Registration Obligations: The company must file a registration statement within 5 business days following the six-month anniversary of the closing to cover resale of underlying shares.
- Liquidated Damages: Failure to file the required registration statement on time triggers damages of 1.5% per month of the aggregate purchase price.
- Automatic Conversion: Series D Preferred Stock automatically converts if the VWAP exceeds $2.00 for 20 consecutive trading days and a registration statement is effective.
- Warrant Expiration: Warrants expire five years from issuance. If the VWAP exceeds $2.50 for 20 consecutive days after six months, unexercised warrants convert to a right to receive $0.01 per share.
Investor Verification Checklist
- Verify the closing date and actual receipt of the $5,000,000 proceeds.
- Confirm the exchange of Series B Preferred Stock for Series D Preferred Stock has been completed.
- Monitor the filing of the registration statement required within six months of closing to avoid 1.5% monthly penalties.
- Review the updated Board of Directors composition to confirm the appointment of the Xmark designee and Lead Investor observer.
- Check for any subsequent amendments to the debt covenant limiting new borrowing to $500,000.